About AlphaVax
AlphaVax is a company based in Durham (United States) founded in 1997. AlphaVax offers products and services including AlphaVaccine Platform and Cancer Immunotherapy Vaccines. AlphaVax operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alphavax Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$135.19 K (USD), Grant
May 17, 2010
-
Investors
HHS
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AlphaVax
AlphaVax offers a comprehensive portfolio of products and services, including AlphaVaccine Platform and Cancer Immunotherapy Vaccines.
Proprietary RNA vector for developing vaccines against infectious diseases.
Vaccines targeting cancers like breast and gastrointestinal types.
People of AlphaVax
Unlock access to complete
Unlock access to complete
Funding Insights of AlphaVax
Investors in AlphaVax
AlphaVax has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for AlphaVax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AlphaVax
Investment portfolio details for AlphaVax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AlphaVax
Detailed financials for AlphaVax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alphavax Comparisons
Peer comparison for AlphaVax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AlphaVax
AlphaVax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of AlphaVax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alphavax
Complete news archive for AlphaVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AlphaVax
AlphaVax was founded in 1997 and raised its 1st funding round 10 years after it was founded.
AlphaVax is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
AlphaVax was founded in 1997 in Durham, United States, within the biotechnology sector. Vaccines targeting infectious disease prevention and cancer immunotherapy are produced by the company. Clinical trials are underway for alpha vaccine candidates against human cytomegalovirus, influenza A virus, and HIV-1. AVX901, a HER2-VRP vaccine for metastatic breast cancer, is among the products. Alphavaccine technology is out-licensed for specific disease and antigen applications to support commercialization.
AlphaVax's top competitors include Merck, Roivant Sciences and AbbVie.
AlphaVax offers AlphaVaccine Platform and Cancer Immunotherapy Vaccines.
AlphaVax has 2 investors. Key investors include HHS, and Military Health.